Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSC for GVHD Prophylaxis in Haplo-SCT
NCT05855707Phase 1Not yet recruiting
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of wharton's jelly mesenchymal stromal cells in graft-versus-host disease (GVHD) and Graft failure, sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Maximum Tolerated Dose at 7 days. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
graft-versus-host disease (GVHD)Graft failure
Beyond the preview
Go deeper on NCT05855707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05855707.